Laboratory of Organoid and Stem-Cell Neurobiology

This research team focuses on building patient-specific stem-cell and organoid models to uncover disease mechanisms and guide therapy development in neurodevelopmental and neurodegenerative disorders, such as autism spectrum disorder, leukodystrophies, Down syndrome, and neural tube defects. Using human iPSCs, we generate brain and spinal-cord organoids enriched with key functional cell types, including oligodendrocytes, microglia, and choroid-plexus epithelium to recapitulate neuron-glia-immune crosstalk in vitro.

The team also develops human blood–brain barrier models for autism spectrum disorder, combining iPSC-derived brain microvascular endothelial cells, pericytes, and astrocytes in microfluidic BBB-chips and Transwell systems. These models are paired with CRISPR genome editing and functional readouts, and we integrate multi-omics with machine learning analytics to map conserved dysfunction signatures and prioritise therapeutic targets.

In parallel, we study the mechanobiological regulation of organoid morphogenesis and disease phenotypes, focusing on how biophysical cues such as matrix stiffness and mechanical stimulation influence tissue self-organization, developmental dynamics, and mechanotransduction pathways. We apply bioengineering strategies to modulate these cues in order to better mimic in vivo-like microenvironments, thereby enhancing organoid maturation, functional performance, and reproducibility.

The overarching goal of this team is to translate organoid-based insights into targeted therapies relevant to Qatar and the region.